Article Text

Download PDFPDF

2106 Salbutamol for analgesia in renal colic
  1. Graham Johnson1,
  2. Andrew Tabner1,
  3. Suzanne Mason2,
  4. Apostolos Fakis1,
  5. Frances Game1,
  6. Rachelle Sherman1
  1. 1University Hospitals of Derby and Burton NHS Foundation Trust
  2. 2University of Sheffield


Aims and Objectives This project was supported by the RCEM Dragon’s Den event in 2014, the inaugural Young Investigator’s Award in 2015, and extensive input from college academics. It was funded by the NIHR RfPB.

Renal colic is pain experienced when a renal calculus causes partial or complete obstruction of the renal outflow tract; pain results from ureteric spasm, increased peristalsis, increased pressure at the renal pelvis, and prostaglandin release with inflammation. Lifetime incidence is approximately 12% in males and 6% in females, with recurrence rates approaching 50%.

The standard analgesic regimes for renal colic are often ineffective and associated with significant side effects; in some studies less than half of patients achieve complete pain relief, a large proportion of patients require rescue analgesia within four hours, and nausea, vomiting and drowsiness are frequently reported.

Salbutamol is a beta agonist in widespread use across healthcare services. It has been hypothesised that beta agonists may reduce the pain of renal colic by promoting ureteral relaxation, reducing the frequency of ureteral contractions, and reducing renal pelvic pressure. Salbutamol has the benefits of parenteral administration, rapid onset of action, and the ability to be used as an outpatient in inhaled form.

Method and Design This randomised, placebo-controlled, double-blind Phase II study provides the first evidence concerning the analgesic effects of salbutamol when added to the standard regime for emergency department patients with renal colic. Participants received conventional analgesia at clinicians’ discretion; they were randomised to receive either 250mcg intravenous salbutamol or placebo. Pain scores were collected using a VAS at baseline, 15, 30, 60, and 120 minutes, and then 4-hourly thereafter.

Results and Conclusion Formal statistical analysis of the results is pending, but provisional results suggest a trend towards benefit that does not reach the pre-determined levels of clinical or statistical significance. Full analysis will be available in time for the conference.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.